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Abstract
This study intended to demonstrate that the thyroid hormone T3 counteracts the onset of a Streptozotocin (STZ) induced
diabetes in wild type mice. To test our hypothesis diabetes has been induced in Balb/c male mice by multiple low dose
Streptozotocin injection; and a group of mice was contemporaneously injected with T3. After 48 h mice were tested for
glucose tolerance test, insulin serum levels and then sacrified. Whole pancreata were utilized for morphological and
biochemical analyses, while protein extracts and RNA were utilized for expression analyses of specific molecules. The results
showed that islets from T3 treated mice were comparable to age- and sex-matched control, untreated mice in number,
shape, dimension, consistency, ultrastructure, insulin and glucagon levels, Tunel positivity and caspases activation, while all
the cited parameters and molecules were altered by STZ alone. The T3-induced pro survival effect was associated with a
strong increase in phosphorylated Akt. Moreover, T3 administration prevented the STZ-dependent alterations in glucose
blood level, both during fasting and after glucose challenge, as well as in insulin serum level. In conclusion we
demonstrated that T3 could act as a protective factor against STZ induced diabetes.
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Introduction
Pancreatic b cell loss is a key factor in the pathogenesis of both
type 1 and type 2 diabetes. Whereas in type 1 diabetes b cell
destruction is caused by an autoimmune process, type 2 diabetes
results from a combination of insulin resistance and impaired b cell
function and survival [1,2]. One of the main processes involved in
the insulin-producing b-cell death is apoptosis, which leads to
insulin deficiency. Therefore, it is conceivable that a valuable
approach to treat or even to prevent the onset of type 1 diabetes,
may imply an anti-apoptotic pro-survival therapy of b cells.
Despite major efforts to halt this epidemic and find a cure for
diabetes, and even though the critical role of b cell apoptosis in the
development and progression of diabetes has been recognized,
current treatment strategies do not include the preservation of
endogenous b cell mass [3]. Novel approaches able to promote
pancreatic b cell reserve and to thwart apoptotic b cell loss are
therefore urgently needed.
The entire b cell mass is dictated by a dynamic balance of
neogenesis, proliferation, cell size and apoptosis [4]. The IRS/
PI3K pathway plays a critical role in the regulation of b cell mass
and the Akt kinase is one of the most promising downstream
molecules of this pathway, which could be targeted to induce
proliferation and survival of b cells [5]. Akt kinase is the principal
mediator of the insulin effects on glucose metabolism. It is
stimulated by a variety of growth factors, including insulin itself.
Studies on mice lacking all the Akt isoforms have highlighted the
importance of the Akt1 isoform on the others in the b cell mass [6].
Moreover, the specific overexpression of a constitutively active
form of Akt 1 in b cells in mice induces increment in both the size
and the number of islet cells [7,8]; in addition, glucose tolerance is
improved and the animals are protected against Streptozotocin-
induced diabetes.
In vitro experiments in insulinoma cell lines and in isolated islets
demonstrated that Akt activation by glucose, insulin, insulin
growth factor (IGF-1) and GLP1 is a key event in the anti-
apoptotic effects of these molecules [9,10,11]. Over the past
decade most components in the insulin signalling pathway have
been identified in murine and human pancreatic b cells. Insulin
signalling has been reported to positively regulate many effects in b
cells such as insulin gene expression, insulin secretion, proinsulin
byosinthesis and cell cycle progression [12]; the same effects are
regulated by glucose. Even the modulation of tribble 3 (TRB3),
a cytoplasmic inhibitor of Akt kinase, altered susceptibility to
high glucose and ER stress induced apoptosis in INS-1 cells,
streghtening the relevance of Akt regulation in b cell mass and
function response [13,14].
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19839Thyroid hormones are widely known for their ability to
influence various cellular processes such as mitogenesis and
differentiation, which are both considered good candidate targets
for counteracting the insorgence of diabetes [15]. We have
previously demonstrated [16] that the thyroid hormone T3
stimulates pancreatic ductal cells, considered as b cells precursor,
towards a b cell-like phenotype. In addition, we showed [17,18,19]
that T3 acts as a mitogenic, pro-survival factor in pancreatic b
cells, and that it can directly activate Akt; taken together, these
results demonstrated that T3 can activate cellular processes strictly
related to b cell function such as cell proliferation and survival, cell
size regulation, protein synthesis and insulin production. More-
over, our recent study demonstrated that T3 can be a survival
factor even for cultured rat islets, counteracting both physiological
and pharmacological b cell death. Even in this case T3 can also act
as a mitogenic factor [20]. These data strongly sustain our
hypothesis that the thyroid hormone T3 can be considered a
promoting factor for b cell function, and outline its possible role in
contrasting the onset of diabetes.
Based on these data, in this study we intended to verify whether
T3 is able to preserve and protect functional b cell mass in STZ
diabetic animals.
Materials and Methods
Animal studies
Six-weeks-old male Balb/c mice were maintained in a
pathogen-free environment in isolator caging system in air
conditioned room at 2361uC in the Cattolica University’s animal
facilities (Rome, Italy) in accordance to the institutional guidelines.
Induction of diabetes
Animals were divided into three experimental groups: CTR,
STZ, STZ+T3. Diabetes was induced by multiple (for 2
consecutive days) low dose (150 mg/kg of body weight) intraper-
itoneal injection of Streptozotocin (STZ) (Sigma-Aldrich, Saint
Louis, Missouri, USA), freshly dissolved in 10 mM Na-citrate
buffer (pH 4,5). STZ-T3 mice were divided into 3 groups and co-
treated with 3 different doses of 3,5,39-Triiodothyronine (T3) (75–
100–150 mg of kg body weight)(Sigma-Aldrich) every 24 hours for
2 consecutive days. The T3 treatment began contemporary to
Streptozotocin.
Evaluation of tissue and immunostaining
Mice were anesthetized with ketamine (70 mg/kg) and domitor
(1 mg/kg) injected intra peritoneally and then sacrified by cervical
dislocation. Pancreata were removed and embedded in killik
cryostat embedding medium (Bio-optica, Milan, Italy). Five
sections (7 mm thick) per pancreata were examined. Cross
sectional islet area was determined on a total of five slides per
pancreas stained with hematoxilin/eosin. Images were analysed
using the Image J software.
For immunohistochemical analysis cryosections were fixed in
cold acetone for 1 minute, air-dried and fixed in 4% paraformal-
dehyde for 10 minutes. Endogenus peroxidase activity was
blocked by incubating slides in a solution of 3% hydrogen pero-
xide for 10 minutes. Unspecific binding was blocked incubating
the slides in 5% goat serum in PBS Ca-Mg Free for 45 minutes
and then for 15 minutes in 1% BSA. Sections were incubated in
humidified chambers overnight at 4uC with the appropriate
primary antibody (insulin 1:100, pAkt 1:50, Akt 1:50, Cell
Figure 1. Thyroid hormone receptors expression. Tissue sections from the different experimental groups of animals have been obtained as
described in the Materials and Methods section. Indirect immunofluorescence for Thyroid Receptor (Red) and Insulin (Greeen) revealed the presence
of TR a/b within the islets and the pancreatic tissue surrounding. Nuclei were counterstained with Hoechst (blue). Data are from 1 or 2 experiments
with similar results (n=5 animals/group). At least ten fields per chamber and three independent cultures were examined. Space bar: 100 mm. Western
Blot analyses were performed as described in Materials and Methods and a specific band corresponding to the Thyroid Receptor a/b was detected.
The expression of B-actin was analyzed as a control for gel loading. At least three different experiments were performed, and a representative one is
shown here. Densitometric absorbance values from three separate experiments were averaged (6 SD), after they had been normalized to B-actin for
equal loading. Data are presented on the right of the Western Blot panel in the histogram as Relative Densitometric Units (y axis). The different
experimental groups are indicated on the x axis. A comparison of the individual treatment was conducted by using Student’s t test. p=0.003.
doi:10.1371/journal.pone.0019839.g001
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anti-mouse or anti-rabbit (Vector Laboratories, Inc., 30 Ingold
Road, Burlingame, CA) then the sections were incubated for an
additional hour with Horseadish Peroxidase Avidin D (Vector
Lab.). Immunoreactivity was revealed using 3,39-diamonobenzi-
dine (DAB, DAKO, north America, Carpinteria, CA) as the
chromogen. Sections were counterstained with hematoxylin.
Terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling TUNEL assay for evaluation of apoptosis was
performed by using In situ cell death detection kit POD (Roche, Basel,
CH) following manufacturer’s instructions. Sections were fixed and
incubated for endogenous peroxidase as described previously and
then permeabilizated in Triton 0,1% in sodium citrate 0,1% for
2 minutes on ice, washed and air-dried. Sections were incubated
1 hour at 37uC in dark with Tunel reaction mixture, then washed
and air-dried. Slides were then incubated with Converted-POD in a
humidified chamber for 30 min at 37uC and for 5 min with DAB
substrate. Sections were counterstained with hematoxylin.
For immunofluorescence analysis, slides were fixed and blocked
as described previously. Primary antibodies (insulin and glucagon,
Cell Signalling, 1:100 and Glut-2, Santa Cruz, 1:50) were
incubated for 1 h at room temperature in humidified chambers.
After 3 washes in BSA 1% in CMF slides were incubated with
secondary antibodies (Polyclonal swine anti-rabbit Immunoglob-
ulin FITC coniugated, DAKO, Denmark, 1:200) for 1 h at room
temperature in dark. Nuclei were counter-stained with 1 mg/ml
Hoechst dye diluited in CMF.
Measurement of insulin mRna by Real Time PCR
Pancreata RNA was extracted by SV Total RNA isolation
System (Promega, 2800 Woods Hollow Road Madison, WI) under
manufacture’s instruction and 1 mg used to synthetize cDNA using
Omniscript RT Kit (Qiagen, Chatsworth, CA). cDNA corre-
sponding to 20 ng of total RNA was used to perform fluorescent-
based real-time PCR quantification using the LightCycler
Realtime PCR apparatus (Roche Inc., Nutley, NJ). Quantitative
PCR was performed using SYBR Premix Ex TAq II (perfect Real
Time)(TAKARA BIO INC. 2 Avenue du President Kennedy,
78100 St Germain en Laye, France) as described by the
manufacturer. The reactions started with a denaturation step at
95uC for 10 seconds, followed by annealing at 56u to 66uC for
5 seconds and elongation at 72uC for 7 to 13 seconds. The
reaction was then heated for 3 seconds at 2uC lower than the
melting temperature of the DNA fragment. Oligoprimer pairs that
allow the amplification of ,200 bp were designed and their
specificity was verified by blasting in the GenBank database.
Reading of the fluorescence signal was taken at the end of the
heating to avoid non-specific signal. A melting curve was
performed to assess non-specific signal. mRNA expression levels
are expressed as number of copies/mg total RNA using a standard
curve of the crossing point vs. logarithm of the quantity. The
standard curve was established using known cDNA amounts of 0,
10
2,1 0
3,1 0
4,1 0
5, and 10
6 copies of 18s and a LightCycler 3.5
program provided by the manufacturer (Roche Inc.). PCR
products were analyzed on a 1,5% agarose gel. The expression
levels of target genes were quantified and normalized by 18S level.
Primers used for PCR amplification were for INS for: 59-
TGGCTTCTTCTACACACCCA-39 and rev:59- TGCAGTAG-
TTCTCCAGCTGG-39 and for 18S for: 59-GGAGAGGGAGC-
CTGAGAAA-39 and 18S rev: 59-CGAAAGAGTCCTGTATT-
GTTATTTT-39.
Caspase activity assay
The caspGLOW
TM red active caspase staining kit (Biovision
Middlefield Way, CA) was used to quantify caspase activity.
Freshly-prepared seven-micrometer cryosections were incubated
with a Red-VAD-FMK at 1:300 diluition in PBS Ca-Mg free at
37uC for 45 min and washed twice with the provided washing
buffer for 10 min. Nuclei were counter-stained with 1 mg/ml
Hoechst dye diluted in PBS.
Western blot analysis
For total protein extraction, pancreata were removed and
immediately freezed in liquid nitrogen. Once freezed tissues were
mechanically homogenized and then lysed for 10 min in ice-cold
lysis buffer containing 1% Tween 20, 10% glycerol, 150 mmol/L
NaCl, 50 mmol/L HEPES pH 7, 1 mmol/L MgCl2, 1 mmol/L
CaCl2, 1 mmol/L NaF, 10 mmol/L Na4P2O7, 2 mmol/L NaVO3,
1 mmol/L phenylmethylsulfonylfluoride, protease inhibitors. The
lysates were sonicated and centrifuged at 12.000 rpm for 30 min.
and the total cellular protein content was measured using Bradford
method (Bio-Rad,Richmond,CA,USA).100 mg oftotalextractper
sample were loaded onto a 10% SDS-polyacrilamide gel,
electrophoresed, and then blotted onto nitrocellulose membranes
(Bio-Rad). Filters were blocked for non specific reactivity by
incubation for 1 h at RT in 5% non–fat dry milk dissolved in PBS
16, 0,1% Tween 20 and incubated for 16 hours at 4uC with the
appropriate primary antibody. Antibodies: anti-Akt and anti-
pSer473Akt (Cell Signalling, Danvers, MA, USA, 1:1000), anti-
Glut-2 (Santa Cruz 1:500), anti Caspase 3 (Millipore,290 Concord
Road, Billerica,MA, USA, 1:200), anti Bax (Santa Cruz 1:250), anti
Tra/b (Santa Cruz 1:200).
At the end the membranes were washed and incubated for
45 min with the appropriate HRP-conjugated secondary antibody
(anti-mouse, anti-rabbit; Sigma-Aldrich 1:4000) in milk 5%, PBS
16, Tween 20 0,1% for 45 min at RT.
Immunoreactivity was visualized by the ECL immune-detection
system (Amersham Corp, Arlington Heights, IL) in according to
Figure 2. Islets analyses. A Histopathology: Tissue section from the different experimental groups of animals have been obtained as described in
the Materials and Methods section. Immunofluorescence for Insulin (green, left panels), and Glucagon (green, middle panel), and Hematoxilin and
Eosin staining (right panels) were performed to analyze histopathological changes in pancreatic islets compared to control mice (CTR). Nuclei were
counterstained with Hoechst (blue) in the IF experiments. Data are from 1 or 2 experiments with similar results (n=5 animals/group). At least ten
fields per chamber and three independent cultures were examined Space bar: 100 mm. Histogram: The percentage of Insulin positive cells was
calculated by counting up to a minimum of 200 cells for ten optical fields (2006) for each sample, randomly taken from two different experiments.
The effect of treatment with T3 was statistically significant versus STZ. Student’s t test: p,0.05 vs STZ+T3. B Islet crossection area: Crossection area
was calculated as described in the Materials and Methods and the results were averaged and represented on the histogram. The presence of T3
significantly counteracts the reduction of islet area and deterioration. At least 10 different islets per sample were analyzed for each experiment. Data
are from 1 or 2 experiments with similar results (n=5 animals/group). The effect of treatment with T3 was statistically significant versus STZ+T3.
Student’s t test: p,0.01 vs STZ+T3. C Real Time PCR: Total RNA was obtained from pancreata from animals of the various experimental groups and
RT-qPCR was performed as described in the Materials and Methods section. Melting point analysis of PCR products for both genes demonstrated
single product formation, as confirmed by gel electrophoresis (on the right). All PCR products were of the expected size and sequence. Normalized
ratios are shown in the histogram; the presence of T3 was able to overcome the STZ inhibition of Insulin gene expression.
doi:10.1371/journal.pone.0019839.g002
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evaluated by densitometric analysis (Image J, Wayne Rusband,
National Institute of Health, USA) and normalized to total B-
actin.
Trasmission electron microscopy
Tissue fragments were fixed with 2% glutaraldehyde in PBS for
2ha t4 uC. Samples were postfixed in 1% osmium tetroxide in
veronal acetate buffer (pH 7.4) for 1 h at 25uCa n ds t a i n e dw i t h
uranyl acetate (5 mg/ml)for 1 h at 25uC, dehydrated in acetone, and
embedded in Epon 812. Ultra-thin sections wereexamined unstained
or poststained with uranyl acetate and lead hydroxide under a
Morgagni 268D electron microscope (Fei, Hillsboro, OR, USA).
Measurements of biochemical parametres
All measurements were performed after 8 h fast.
IPGTT. Glucose tolerance test was carried out 48 hours after
STZ and T3 treatment by an intraperitoneal injection of glucose
(3 g/kg of body weight) to overnight fasted mice. Glucose and
insulin concentrations were determinated in tail vein blood at 0, 30
and 120 min after glucose injection by using Ascenzia Breeze
(Bayer AG,51368 Leverkusen, Germany) and Mercodia ultrasen-
sitive mouse insulin ELISA kit (Mercodia, Uppsala, Sweden).
ITT. Mice received an intraperitoneal insulin injection (0,75
U/Kg of bodyweight) under fast condition. Blood glucose con-
centration was determinated at 0, 30 and 120 min after injection by
using Ascenzia Breeze (Bayer AG,51368 Leverkusen, Germany).
RNA isolation and RT-PCR analysis
Total cellular RNA was isolated from livers by using SV Total
RNA Isolation kit (Promega, Madison, WI), according to
manufacturer’s instructions. RNA (1 mg) was subjected to reverse
transcription (RT) by using a cDNA synthesis kit OmniScript
(QIAGEN, Chatsworth, CA). cDNA was amplified to determine
desiodase I expression using the following primer pairs : (mDioI)
59-AAGAGGCTCTGGGTGCTCTTGG-39 and 59-GGTTCT-
GGTGATTTCTGATGTC-39. Amplification was performed for
30 cycles, after a first denaturing step at 94uC for 5 min, at a
denaturing temperature of 94uC for 30 sec, at annealing tem-
perature of 55uC for 30 sec and at an extension temperature of
72uC for 30 sec. PCR products were electrophoresed onto a 1.5%
agarose gel containing ethidium bromide (0.5 mg/ml) and
visualized under UV light. 18s expression levels were analyzed
as a control for RNA quality using the following primers for the
amplification 59-GGAGAGGGAGCCTGAGAAA-39 and: 59-
CGAAAGAGTCCTGTATTGTTATTTT-39.The relative inten-
sity of the bands was quantitated by densitometric analysis
(ImageJ, Wayne Rusband, National Instutite of health, USA)
and normalized to the co-amplified 18s cDNA fragments.
All primers were synthesized by MWG Oligo Synthesis Report
(Eurofins MWG Operon, Edersberg, Germany)
Statistical analysis
Different statistical analyses were performed depending on the
experimental type and are indicated in the relative Figure legends.
Results
T3 treatment preserves islets morphology and dimension
To study the in vivo effects of the thyroid hormone T3, we used
Balb/c mice. Diabetes has been induced with a ‘‘multiple low dose
Streptozotocin injection protocol’’, as described in the Materials
and Methods section. The thyroid hormone action is mainly
mediated through two thyroid receptor isoforms, namely TRa and
TRb. Our previous data evidenced that T3 action on pancreatic b
cells and islets is predominantly mediated through the thyroid
receptor b1 [19]. Hence even if the expression of the thyroid
hormone receptors a and b in murine pancreatic islets has already
been described [21], we confirmed this in our model by immu-
nofluorescence and western blot analyses (Fig. 1). Mice were
divided into three separate groups of study, namely the control one
(CTR), which received vehicles alone; the Streptozotocin one
(STZ), which received 2 intraperitoneal injections of STZ every
24 hours for 2 days; and the Streptozotocin+T3 one (STZ+T3),
which received both T3 and STZ, ip every 24 hours, for 2 days.
At the end of treatments, mice were sacrificed, and pancreata
were excised. Size and shape of the islets were evaluated by
hematoxylin/eosin staining, while the expression of insulin as well
as of glucagon by immunofluorescence analysis (Fig. 2A). At the
morphological level, as expected, islets from STZ-treated mice
showed disarray of cellular architecture, irregular boundaries,
reduced area and diminished b cell mass, when compared to
control mice (Fig. 2A).
By contrast, T3 administration significantly prevented the
decrease in b cell mass and islets area, counteracting the
morphological changes induced by STZ. The b cell mass was
directly analyzed by morphometry and the crossection area of the
islets was measured as described in the Materials and Methods
section. In fact, as shown in Figure 2B while the area of the
Streptozotocin islets was significantly reduced, the decrease was
completely overcome by the T3 treatment. Moreover, the T3-
induced preservation of islets shape and size was not due to growth
of undifferentiated mass, since no increase in the number of Ki67+
cells was observed (data not shown), excluding an eventual T3
caused indifferentiated mass growth. To better highlight the
beneficial thyroid hormone effects on b cell mass and function,
Real Time RT-PCR for Insulin has been performed. Typical
standard curves plotted by the Lightcycler were obtained for Ins
Figure 3. Apoptosis and survival. A Apoptosis measurement Tissue sections from the different experimental groups of animals have been
obtained as described in the Materials and Methods section. Caspases activity (left panel, red) was detected by CaspGLOW and Tunel assay (right
panel) was visualized by Immunohistochemistry. At 48 h of STZ alone apoptotic nuclei were clearly detectable within the islets, while in the samples
exposed contemporary to T3 apoptotic nuclei were hardly detectable within the islets. At least 10 different islets per sample were analyzed for each
experiment. Data are from 1 or 2 experiments with similar results (n=5 animals/group). Space bar: 100 mm. Histogram: The percentage of Tunel or
Caspase positive cells was calculated by counting up to a minimum of 200 cells for ten optical fields (2006) for each sample, randomly taken from
two different experiments. The effect of treatment with T3 was statistically significant versus STZ. Student’s t test: p,0.01 vs STZ. B Western Blot:
Western Blot analyses were performed as described in Materials and Methods on protein extracts from the various experimental groups and a specific
band corresponding to Bax and Casapase3 was detected. As shown, while the presence of STZ clearly induced the expression of Bax and the
activation of Casp 3, the presence of T3 was able to counteract STZ action, maintaining Bax and Casp 3 levels comparable to the CTR samples. The
expression of B-actin was analyzed as a control for gel loading. At least three different experiments were performed, and a representative one is
shown here. Densitometric absorbance values from three separate experiments were averaged (6 SD), after they had been normalized to B-actin for
equal loading. Data relative to each protein are presented on the right of the Western Blot panel in the histogram as Relative Densitometric Units (y
axis). The different experimental groups are indicated on the x axis. A comparison of the individual treatment was conducted by using Student’s t
test. p=0.003.
doi:10.1371/journal.pone.0019839.g003
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in the Materials and Methods section. Indirect Immunofluorescence for Glut-2 (green) revealed the presence of the Glucose transporter within the
islets, clearly detectable. Nuclei were counterstained with Hoechst (blue). As shown with T3 treatment, no differences either in the expression levels
or in the localization of the Glucose transporter Glut-2 was observed. On the other hand, the presence of the STZ was sufficient to cause a strong
disarray in both expression and localization of Glut-2 in the islets. Data are from 1 or 2 experiments with similar results (n=5 animals/group). At least
ten fields per chamber and three independent cultures were examined. Space bar: 100 mm. Western Blot: Western Blot analyses were performed as
described in Materials and Methods on protein extracts from the CTR and the T3 treated animals and a specific band corresponding to Glut-2 was
detected. The presence of T3 did not provoke any change in the Glut-2 expression, as compared to B-actin expression. The expression of B-actin was
analyzed as a control for gel loading. At least three different experiments were performed, and a representative one is shown here. Densitometric
absorbance values from three separate experiments were averaged (6 SD), after they had been normalized to B-actin for equal loading. Data are
presented on the right of the Western Blot panel in the histogram as Relative Densitometric Units (y axis). The different experimental groups are
indicated on the x axis. A comparison of the individual treatment was conducted by using Student’s t test. P,0.003.
doi:10.1371/journal.pone.0019839.g004
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for both genes demonstrated single product formation, as
confirmed by gel electrophoresis. As shown in the histogram,
(Fig. 2C) whether the presence of Insulin mRNA was barely
detectable in the STZ treated pancreata, the thyroid hormone
treatment was sufficient to maintain the Insulin gene levels
comparable to control (65%), strongly overcoming the STZ
inhibition.
T3 counteracts STZ induced islets apoptosis
Based on our previous observations in b cell lines and in ex vivo
cultured islets, where the presence of T3 was sufficient to
completely overcome the ongoing apoptotic process, and consid-
ering the evident preservation of the b cell mass in T3 treated
mice, we wanted to verify whether T3 treatment could protect the
animals from STZ-induced effects by preventing apoptotic cell
death. To this aim, Tunel analyses and active caspases staining
were assessed in pancreata from the different groups of mice. As
shown in Figure 2, STZ treatment results in a much higher
number of Tunel+ and active caspases+cells within the islets, when
compared to control. These results demonstrate that the acute
oxidative injury caused by STZ treatment induces a high level of
cell death. By contrast, T3 co-treatment prevents STZ-induced
cell death, lowering the number of Tunel+ and active caspases+-
cells to levels comparable to control samples, as shown in the
histogram of Fig. 3A.
To deepen into the molecular changes induced by T3 in the
apoptotic cascade, two major proapoptotic molecules have been
analyzed by Western Blot, which are moreover both targeted by
the Akt action. As shown in the Figure 3B, while STZ clearly
induced BAX expression, the T3 can maintain its levels com-
parable to the control ones. In agreement, even the activation of
the caspase 3, a Bax downstream, which is clearly evident and
strong in the STZ samples, shows basal levels in both the control
and the STZ+T3 ones, indicating that T3 can contrast its
activation by STZ.
T3 does not influence Glut-2 expression or localization
Since it is known that the glucose-analogue STZ requires the b
cell glucose transporter Glut-2 to enter the cell and to exert its
apoptotic effect [22], we investigated Glut-2 expression and
localization in the islets by immunofluorescence analysis. As shown
in Figure 4, the STZ could completely disarray the Glut-2
expression and localization, consistently with its negative effect on
the whole islet structure; on the other hand both control and
STZ+T3 islets showed good localization and levels of the Glucose
transporter. Interestingly, T3 treatment did not alter either
expression or localization of Glut-2, ruling out the possibility that
T3 could counteract apoptosis in b cells by preventing STZ entry
via Glut-2. In addition, since Glut-2 is the key responsible in the
glucose uptake by the b cell, we can hypothesize that T3 effects are
not due to any alteration in the glucose entry in the cells.
T3 preserves ultrastructure of b cells against STZ
To further evaluate the morphological recovery induced by
T3 treatment in STZ-treated mouse islets, TEM analysis
was performed. Figure 5 contrasts the difference in ultrastruc-
tural appearance of well-granulated b cells in an islet of
STZ+T3 mouse, as well as a CTR mouse, versus the extensively
degranulated appearance of an islet from a STZ mouse. The
marked reduction in insulin storage granules was generally
associated with a dilatation of the rough endoplasmic reticulum.
b cells containing mitochondria with a less dense matrix and partly
damaged cristae were also observed, while large vacuoles, swollen
cisternae of endoplasmic reticulum and myelinic bodies were also
evident. These ultrastructural features are consistent with extreme
secretory stress placed on residual b cells. In contrast, the b-cells of
STZ+T3 treated islets were characterized by an overall unaltered
ultrastructural morphology, which was similar to control islets.
The cytoplasm contained numerous granules of the round
medium-dense core type or with angular or round crystalline
material surrounded by a large clear halo.
T3 stimulates islets Akt activation
Previously, we demonstrated that T3 is able to activate the Akt
signalling in pancreatic b cells and, most importantly, that this
activation is the key event in the T3 action on pancreatic b cell
function and survival; hence, we sought to verify whether the
observed T3-induced anti-apoptotic action may depend on Akt
activation/phosphorylation. As shown in Figure 6, immunostain-
ing for pAkt (Ser473) demonstrated that, while in STZ-treated
islets Akt activation was significantly inhibited, when T3 was
Figure 5. Ultrastructure of b cells. Trasmission electron micrographs
of STZ and STZ+T3 treated pancreatic islets compared to control (Uranyl
acetate/lead citrate; space bar 1 mm). Nu, nucleus; MB, myelinic bodies.
The ultrastructure of the b cells was affected by STZ and maintained
unaltered by the addition of T3. Data are from 1 or 2 experiments with
similar results (n=5 animals/group).
doi:10.1371/journal.pone.0019839.g005
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described in the Materials and Methods section. Immunohistochemistry for pAKT (Ser 473) was performed as described in the Materials and Methods.
The presence of T3 clearly provoked an increment in Akt activation, as compared to total Akt expression (data not shown) Data are from 1 or 2
experiments with similar results (n=5 animals/group). At least ten fields per chamber and three independent cultures were examined Space bar:
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actually maintained comparable to control, untreated islets. This
observation was further confirmed by Western blot analysis (Fig. 6,
right panel). Furthermore considering that Akt survival action
includes the regulation of some proapoptotic factors, as Bax and
caspase 3, the evidence for Akt activation can easily be related to
the shown Bax and Casp 3 inhibition by T3.
These results, together with our previous evidences in b cell
lines and in islets, strongly suggest that T3 exerts its b cell
protective effect at least in part through the Akt signalling.
T3 preserves glucose responsiveness in STZ treated mice
Metabolic parameters were assessed in mice. After STZ
injection mice were diabetic with significant fasting hyperglycemia,
as described below, glycosuria and hypoinsulinemia when
compared with age-matched control mice and STZ+T3 mice.
At the time of sacrifice body weight was still similar between mice
injected with either STZ or STZ+T3, showing a little decrease
only in few case of STZ injected animals. This was presumably
due to dehydration and protein wasting associated with diabetes.
Thus, the STZ injection protocol we used generated an
experimental model of type 1 diabetes, as expected.
Considering that T3 increases b cell function and survival, as we
previously demonstrated, and that it maintains b cell mass in STZ-
treated mice, it is conceivable that T3 may act as an anti-diabetic
factor, ensuring euglycemic status by preserving b cell mass. We
thus analyzed the ability of the different groups of mice to respond
to an ip glucose tolerance test. Among the 25 mice receiving STZ,
21 became overlay diabetic (blood glucose .250 mg/dl); while 4
showed borderline elevated blood glucose (300.200 mg/dl). In
contrast, among the 25 mice treated with T3 together with STZ,
only 4 became diabetic; the remaining 18 maintained normal
blood glucose levels (,150 mg/dl), while 3 died. In addition,
glucose tolerance test evidenced that while the Streptozotocin
treated mice completely lost their ability to normally respond to
glucose loading, the presence of T3 preserves the ability of mice to
restore their normal glycemia 120 min after glucose loading and
maintains the serum glucose levels in the euglycemic range (Fig. 7).
T3 preserves islets function in STZ treated mice
Finally, we assayed serum insulin levels to analyze the effect of
T3 treatment on islets function. As shown in Figure 7 (A), STZ
treatment induced a significant decrease in the insulin response, as
showed by the lower levels of serum insulin at the different time
points, according to the affected ability of control glucose blood
levels; on the other hand when T3 was administered at the same
time of STZ, serum insulin levels were comparable to the con-
trol (Fig. 7B), suggesting that T3 treatment preserves insulin
production, preventing STZ effects. These final observations su-
pported the hypothesis on that T3 acts as an antidiabetic in vivo,
preserving b cell mass, counteracting b cell apoptosis and regu-
lating the insulin response, via the Akt signalling.
To better characterize the physiology of our mice, we decided
to exclude the occurence of Insulin intolerance by an Insulin
Tolerance test. As shown in the histogram in Figure 7C, all
animals showed an adequate Insulin responsive, although, as
expected, glucose blood levels were higher in the animals treated
with STZ.
In all the experiments described above, the serum levels of FT4
and FT3 were evaluated by chemiluminescence to exclude
the presence of hyperthyroidism in the animals; moreover the
expression of the deiodinase 1 in liver was not altered by the
treatment, as shown in Figure 7D, indicating a condition of
euthyroidism in the T3 treated mice.
Discussion
In this paper we describe a novel protective action of thyroid
hormone T3 from STZ-induced diabetes in vivo. Although recent
clinical evidences indicate that thyroid hormone treatment can
ameliorate diabetic condition [26,27], our study is the first one to
focus on b cell function in a diabetic animal model (STZ-treated
mice) in the presence of T3 administration.
At first, T3 treatment prevented STZ-induced islets deteriora-
tion, as shown by the maintenance of the islet structure, size and
consistency. Indeed, while STZ treatment induced reduction in
islets size and cell number, the morphology of the islets, the
abundance and distribution of insulin-, as well as glucagon-,
expressing cells in the animals treated with T3 and STZ, remained
comparable to islets derived from control mice. Preservation of
islets morphology was also confirmed at the ultrastructural level,
where the presence of T3 prevented the induction of STZ-induced
features of cell damage (clumped chromatin, disorganized insulin-
containing granules, altered mitochondria, endoplasmic reticulum
and vacuoles morphology). The observed ability to preserve the
islets appearance was associated with a protective role of T3 on
STZ-induced b cell death, as shown by both Tunel analysis and
caspases activation. The STZ-induced cell death observed within
the islet was almost completely prevented by T3. It is known that
Streptozotocin enters b cells via the glucose transporter Glut-2 and
induces islets deterioration by inducing b cells apoptosis [22]. We
sought that neither expression or localization of Glut-2 was altered
by T3 treatment, ruling out that the observed effects may be
dependent on impairment in Streptozotocin internalization. These
results are consistent with our previous observations where we
showed that T3 may be considered a mitogenic and survival factor
for pancreatic b cells in vitro : it preserved, indeed survival and
function in freshly isolated islets in culture and protected cultured
b cells from pharmacological induced apoptosis [17,19]. Taken
together our results show that the main mechanism leading to the
increase in b cell mass, survival and function, when T3 is
administered together with STZ, is based on the prevention of
STZ-induced b cell apoptosis.
Increasing evidences indicate that the decrease of the functional
b-cell mass is the hallmark of both Type 1 and Type 2 diabetes,
resulting in the absolute or relative insulin insufficiency in both
conditions. In this context, b-cell apoptosis and impaired
proliferation, consequences of hyperglycemia, are features that
may be present in all forms of diabetes, suggesting that the
classification of diabetes should be revalued [23,24,25]. b cell
100 mm. Western Blot: Western Blot analyses were performed as described in Materials and Methods and a specific band corresponding to the
phosphorylated Akt (Ser 473) was detected. The expression of total Akt was analyzed as a control for gel loading. The presence of T3 clearly provoked
an increment in Akt activation (Ser 473), as compared to total Akt expression. At least three different experiments were performed, and a
representative one is shown here. Densitometric absorbance values from three separate experiments were averaged (6 SD), after they had been
normalized to Akt for equal loading. Data relative to each protein are presented on the right of the Western Blot panel in the histogram as Relative
Densitometric Units (y axis). The different experimental groups are indicated on the x axis. A comparison of the individual treatment was conducted
by using Student’s t test. P,0.001.
doi:10.1371/journal.pone.0019839.g006
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highlighting the urgence to identify factors able to specifically
target the b cell mass, avoiding any b cell toxic side effects.
The PI3K/Akt pathway is a common pathway activated by a
variety of growth factors to stimulate cell growth and survival. In
particular, Akt activation has been shown to induce b cell
proliferation, survival, mass and function [5,28]. Thus, factors able
to stimulate Akt have gained relevance in the search of new anti-
diabetic strategy. We showed in this paper that the observed T3-
induced anti-apoptotic effects are associated with activation of the
Akt signalling pathway in the islets. This is consistent with recent
data showing the ability of the thyroid hormone to stimulate Akt in
neurons [29], in vascular myocytes [30] and in other cell types
[31]. In addition, we previously demonstrated that T3 stimulates
Akt in pancreatic b cells in vitro [18], leading to the activation of
mTOR, GSK3B, B-catenin and others [19]; in the present study
we did not deepen into the Akt pathway, but considering our in
vitro data, it is conceivable that the survival action of T3 in mice
might involve mainly the same mechanisms. The important
outcome of the observed T3 protective effects in b cell survival and
function is the preservation of pancreatic metabolic activity.
Indeed, we showed that T3 administration actually preserves an
intact response to glucose, and keeps plasma insulin levels in STZ-
treated mice comparable to those in control mice; moreover, we
showed that both STZ and STZ+T3 treated mice do not develop
insulin resistance.
While b cell loss by apoptosis is a recognized feature of both
type 1 and type 2 diabetes, approaches to block this process are
limited, so far. Currently, the main goal for diabetes treatment is
the maintenance of glucose homeostasis as close to normal as
possible in order to avoid the devastating complications of this
disease. These treatments include oral hypoglycemics and insulin
sensitizers, different insulin preparations administered daily by
multiple injections, continuous insulin pumps and, in some T1D
patients, transplantation of the whole pancreas or islets. None of
these approaches is focused on the maintenance of endogenous b
cell mass, though it has been shown that even a small amount of
preserved endogenous insulin secretion has great benefits in terms
of clinical outcome [32]. Therefore, finding a molecule that could
be useful to block b cell apoptosis and thereby preserve and
enhance endogenous b cell mass would represent a major
breakthrough. The results presented in this study suggest that
T3 may actually be a good candidate.
To this aim, however, therapeutic protocol should be accurately
designed, in terms of both doses and time intervals, to avoid side
effects. It is known indeed that excess of thyroid hormones
production by the thyroid gland or by exogenous thyroid
hormones administration, results in hyperthyroidism or thyrotox-
icosis, characterized by tachycardia, with possible atrial arrythmias
and heart failure, muscle wasting, osteoporosis in post-menopausal
women, and other symptoms [33]. However, thyroid hormone
excess also results in beneficial effects, including the metabolic
ones. Given the widespread effects of thyroid hormones on the
physiology of multiple organs, the chance to use them in a
therapeutical fashion remains attractive. In this context, it has
been recognized that the induction of a subclinical hyperthyroid-
ism, especially if temporary induced, might be well tolerated by
patients and could be accepted in some clinical cases. As reported
by Kaptein et al [34], thyroid hormone treatment in obese patients
with nonthyroidal illnesses provoked only a subclinical risk and no
significant side effects concerning either weight loss or heart rate;
neither mortality was worsened by THs treatment. In the present
study, animals, which received thyroid hormone T3 for 48 h, did
not show any significant risky alterations in the thyroid status and
did not develop any hyperthyroidism.
Next to the possibility to use T3 (or analogues) in vivo to
counteract diabetes, given the pro-survival and antiapoptotic
activity on b cells described, T3 administration may also be
considered to improve setting for islets transplantation. A major
impediment indeed to islet transplantation is the large number of
islets required in order to confer insulin independence, resulting in
the need of several organ donors [35]. This fact is in sharp contrast
to the known small amount of b cell mass necessary for the
mainteinance of glucose homeostasis in vivo. It is therefore assumed
that a large fraction of transplanted islets undergoes apoptosis and
is lost. We recently demonstrated that the administration of T3 to
the islets in culture preserves their vitality against both physiolog-
ical and pharmacological cell death. T3 treatment makes islets less
susceptible to stress during the transplantation, preventing b cell
loss, reducing the number of the required islets and thereby
improving the outcome of islets transplantation.
In conclusion, our findings demonstrate for the first time that
T3 administration counteracts STZ-induced diabetes, as being a
pro-survival, anti-apoptotic factor for b cells, and thus preserves
glucose sensing machinery. Altogether these results suggest that T3
can be considered or added to diabetes therapy.
As both type 1 and type 2 diabetes are diseases where deficiency
in b cell mass and function is pathogenic, the ability of thyroid
hormone to preserve islet mass without loss of b cell differentiated
function makes T3 an attractive factor for future therapies for
diabetes.
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Figure 7. Phisiological parameters. A, B: Analysis of blood glucose and Insulin levels after intra-peritoneal glucose tolerance test (upper panels).
Glycemia was measured by glucometer, while Insulin concentration was assessed by ELISA assay, as described in the Materials and Methods section.
Oral administration of T3 significantly reduces severity and progression of STZ-induced diabetes in Balb/c mice and assured normal Insulin
responsiveness. C: Insulin tolerance was performed (lower panel) after intra peritoneal glucose injection. Insulin was injected intraperitoneally after
glucose to the different experimental groups of animals. Glycemia was measured by glucometer. Results represent the mean 6 SE of three separate
experiments. Grey: control black:STZ white:STZ+T3. D RT-PCR: Total RNA was extracted from liver from mice of the different experimental groups and
RTPCR was performed as described in the Materials and Methods section. A single product was obtained for each gene, as showed by agarose
electrophoresis. All PCR products were of the expected size and sequence. The presence of T3 did not induce any change in the DIO1 expression, as
normalized to 18s.
doi:10.1371/journal.pone.0019839.g007
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